Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab
- PMID: 19933906
- DOI: 10.1200/JCO.2009.25.0233
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab
Comment in
-
Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28. J Clin Oncol. 2010. PMID: 20585096 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
